$Nanobiotix(NBTX)$ 7%涨幅。食管腺癌。
NBTX announced initial data from a Phase 1 study of JNJ-1900 (NBTXR3) for locally advanced esophageal adenocarcinoma, presented at ASTRO 2025. The treatment was well-tolerated in 13 patients, with an 85% disease control rate and 69% objective response rate (6 complete, 3 partial). Recruitment of 17 additional patients is ongoing. The study is sponsored by MD Anderson Cancer Center。市值已经快10亿。#Seeking# #biotech#